Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
50 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Perennial Allergic Rhinitis - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Perennial Allergic Rhinitis - Pipeline Review, H1 2015', provides an overview of the Perennial Allergic Rhinitis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Perennial Allergic Rhinitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Perennial Allergic Rhinitis and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Perennial Allergic Rhinitis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Perennial Allergic Rhinitis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Perennial Allergic Rhinitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Perennial Allergic Rhinitis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Perennial Allergic Rhinitis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Perennial Allergic Rhinitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Perennial Allergic Rhinitis Overview 6 Therapeutics Development 7 Pipeline Products for Perennial Allergic Rhinitis - Overview 7 Pipeline Products for Perennial Allergic Rhinitis - Comparative Analysis 8 Perennial Allergic Rhinitis - Therapeutics under Development by Companies 9 Perennial Allergic Rhinitis - Pipeline Products Glance 10 Late Stage Products 10 Clinical Stage Products 11 Perennial Allergic Rhinitis - Products under Development by Companies 12 Perennial Allergic Rhinitis - Companies Involved in Therapeutics Development 13 Adamis Pharmaceuticals Corporation 13 FAES Farma SA 14 GenMont Biotech Inc. 15 GlaxoSmithKline plc 16 Hanmi Pharmaceuticals, Co. Ltd. 17 Merck & Co., Inc. 18 Pfizer Inc. 19 Shionogi & Co., Ltd. 20 VentiRx Pharmaceuticals, Inc. 21 Perennial Allergic Rhinitis - Therapeutics Assessment 22 Assessment by Monotherapy Products 22 Assessment by Combination Products 23 Assessment by Target 24 Assessment by Mechanism of Action 26 Assessment by Route of Administration 28 Assessment by Molecule Type 30 Drug Profiles 32 (montelukast sodium + levocetirizine dihydrochloride) - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 APC-3000 - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 bilastine - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 desloratadine - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 fluticasone furoate - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 GMNL-32 - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 PF-06444752 - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 PF-06444753 - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 S-555739 - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 VTX-1463 - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 Perennial Allergic Rhinitis - Recent Pipeline Updates 44 Perennial Allergic Rhinitis - Dormant Projects 47 Perennial Allergic Rhinitis - Discontinued Products 48 Appendix 49 Methodology 49 Coverage 49 Secondary Research 49 Primary Research 49 Expert Panel Validation 49 Contact Us 50 Disclaimer 50
List of Tables Number of Products under Development for Perennial Allergic Rhinitis, H1 2015 7 Number of Products under Development for Perennial Allergic Rhinitis - Comparative Analysis, H1 2015 8 Number of Products under Development by Companies, H1 2015 9 Comparative Analysis by Late Stage Development, H1 2015 10 Comparative Analysis by Clinical Stage Development, H1 2015 11 Products under Development by Companies, H1 2015 12 Perennial Allergic Rhinitis - Pipeline by Adamis Pharmaceuticals Corporation, H1 2015 13 Perennial Allergic Rhinitis - Pipeline by FAES Farma SA, H1 2015 14 Perennial Allergic Rhinitis - Pipeline by GenMont Biotech Inc., H1 2015 15 Perennial Allergic Rhinitis - Pipeline by GlaxoSmithKline plc, H1 2015 16 Perennial Allergic Rhinitis - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2015 17 Perennial Allergic Rhinitis - Pipeline by Merck & Co., Inc., H1 2015 18 Perennial Allergic Rhinitis - Pipeline by Pfizer Inc., H1 2015 19 Perennial Allergic Rhinitis - Pipeline by Shionogi & Co., Ltd., H1 2015 20 Perennial Allergic Rhinitis - Pipeline by VentiRx Pharmaceuticals, Inc., H1 2015 21 Assessment by Monotherapy Products, H1 2015 22 Assessment by Combination Products, H1 2015 23 Number of Products by Stage and Target, H1 2015 25 Number of Products by Stage and Mechanism of Action, H1 2015 27 Number of Products by Stage and Route of Administration, H1 2015 29 Number of Products by Stage and Molecule Type, H1 2015 31 Perennial Allergic Rhinitis Therapeutics - Recent Pipeline Updates, H1 2015 44 Perennial Allergic Rhinitis - Dormant Projects, H1 2015 47 Perennial Allergic Rhinitis - Discontinued Products, H1 2015 48
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.